Related Experiment Video
Updated: Jul 14, 2026
08:55
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Melanocortin interventions in cachexia: how soon from bench to bedside?
1Division of Endocrinology, University of Virginia, Charlottesville, Virginia 22908, USA. mdd5z@virginia.edu
Current Opinion in Clinical Nutrition and Metabolic Care
|June 15, 2007
Summary
Targeting the melanocortin system offers a promising strategy for treating cachexia, a wasting condition. Melanocortin antagonism, particularly via the melanocortin-4 receptor, shows potential in preclinical models for improving food intake and body mass.
Area of Science:
- Neuroscience
- Endocrinology
- Metabolic Diseases
Background:
- Cachexia is a complex metabolic syndrome characterized by anorexia and wasting, associated with chronic diseases like cancer, heart failure, and renal failure.
- The melanocortin system, located in the hypothalamus and brainstem, is implicated in regulating appetite and energy balance, and its dysregulation may contribute to cachexia symptoms.
Purpose of the Study:
- This review focuses on cachexia treatment interventions that target the melanocortin system through antagonism.
- Investigate the potential of melanocortin antagonism as a therapeutic strategy for cachexia.
Main Methods:
- Review of recent scientific literature on the melanocortin system's role in cachexia.
- Analysis of studies investigating small molecule antagonists of the melanocortin-4 receptor.
- Examination of evidence for melanocortin antagonism through agents like ghrelin and eicosonoic acid.
Main Results:
- The melanocortin system's physiology and responsiveness to inflammatory cytokines are described.
- Small molecule melanocortin-4 receptor antagonists have demonstrated efficacy in animal models of cachexia.
- These antagonists, administered peripherally, improved food intake and lean body mass in models of cancer and renal failure-induced cachexia.
Conclusions:
- Cachexia is a severe condition lacking effective treatments, highlighting the need for novel therapeutic approaches.
- Melanocortin system antagonism presents a logical therapeutic target for alleviating cachexia symptoms.
- While preclinical data are promising, clinical application data for melanocortin antagonism in cachexia are currently unavailable.
Related Concept Videos
01:26Cushing Syndrome I: Introduction
Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:19Cushing Syndrome II: Pathophysiology
Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...